HC Wainwright Issues Negative Forecast for Biohaven Earnings

Biohaven Ltd. (NYSE:BHVN) – Analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for Biohaven in a research report issued on Wednesday, August 12th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($0.86) per share for the quarter, down from their previous forecast of ($0.84). HC Wainwright currently has a “Neutral” rating and a $10.00 target price on the stock. The consensus estimate for Biohaven’s current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Biohaven’s Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.44) EPS, FY2027 earnings at ($3.05) EPS, FY2028 earnings at ($2.41) EPS and FY2029 earnings at ($1.41) EPS.

Other equities analysts have also issued reports about the company. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Biohaven in a research note on Friday, June 26th. Needham & Company LLC set a $11.00 price target on shares of Biohaven in a report on Monday, June 29th. Royal Bank Of Canada increased their target price on Biohaven from $22.00 to $23.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biohaven in a research note on Tuesday, June 2nd. Finally, Bank of America reaffirmed an “underperform” rating and issued a $11.00 price objective (down from $12.00) on shares of Biohaven in a research note on Monday, June 29th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $21.75.

Biohaven Price Performance

Shares of NYSE:BHVN opened at $13.67 on Monday. The firm has a fifty day moving average price of $14.62 and a 200 day moving average price of $11.76. Biohaven has a fifty-two week low of $7.48 and a fifty-two week high of $18.57. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -2.95 and a beta of 1.26. The company has a debt-to-equity ratio of 21.23, a quick ratio of 4.73 and a current ratio of 4.73.

Biohaven (NYSE:BHVN) last released its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.15).

Hedge Funds Weigh In On Biohaven

Hedge funds and other institutional investors have recently modified their holdings of the business. PNC Financial Services Group Inc. boosted its position in shares of Biohaven by 113.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after purchasing an additional 1,268 shares during the period. IFP Advisors Inc boosted its position in shares of Biohaven by 55.4% in the 4th quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock valued at $46,000 after purchasing an additional 1,450 shares during the period. EverSource Wealth Advisors LLC grew its position in Biohaven by 178.4% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock worth $46,000 after purchasing an additional 2,583 shares during the last quarter. Arax Advisory Partners increased its holdings in shares of Biohaven by 943.3% in the fourth quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock valued at $55,000 after purchasing an additional 4,443 shares during the period. Finally, Essential Partners LLC raised its holdings in Biohaven by 31.7% during the first quarter. Essential Partners LLC now owns 9,020 shares of the company’s stock worth $76,000 after purchasing an additional 2,169 shares in the last quarter. 88.78% of the stock is owned by hedge funds and other institutional investors.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.